Orbinski attended
Dawson CEGEP in Montreal, received a bachelor's degree in psychology from
Trent University (1984), a medical degree from
McMaster University Medical School (1990), and a master's degree in international relations from the University of Toronto's
Munk Centre for International Studies (1998). Following medical school, Orbinski held a
Medical Research Council of Canada fellowship to study pediatric HIV in Sub-Saharan Africa. In 1991, he began working internationally with
Médecins Sans Frontières (MSF). After his first mission in Peru, Orbinski served as MSF's Medical Coordinator in Baidoa during the
Somali Civil War and famine of 1992–93, and in Jalalabad, Afghanistan during the winter of 1994. He was subsequently MSF's Head of Mission in Kigali during the
Rwandan genocide of 1994, and in Goma, Zaire during the
refugee crisis in 1996–97. Orbinski was elected President of the International Council of MSF from 1998 to 2001. As international president of MSF, he represented the organization in numerous humanitarian emergencies and on critical humanitarian issues including in the Sudan, Kosovo, Russia, Cambodia, South Africa, India and Thailand, among others. Orbinski also represented MSF at the
UN Security Council, in many national parliaments, to the
World Health Organization, as well as the
UN High Commissioner for Refugees. He accepted the 1999
Nobel Peace Prize awarded to MSF for its pioneering approach to medical humanitarianism, and most especially for its approach to bearing witness. As MSF International Council president, he allocated the Nobel Prize money to launch MSF's
Campaign for Access to Essential Medicines that year. On September 11, 2001, Orbinski was in Lower Manhattan to present at a UN meeting on Neglected Tropical Diseases. He witnessed the
terrorist attacks on the
World Trade Center and participated in relief efforts for injured people ferried across the Hudson River. From 2001 to 2004, Orbinski co-chaired MSF's Neglected Diseases Working Group, which created and launched the
Drugs for Neglected Diseases Initiative (DNDi). The DNDi is a global not-for-profit research consortium focused on developing treatments for tropical diseases of the developing world that are largely neglected by profit-driven research and development companies. Since its inception, the DNDi has engaged in international advocacy for neglected tropical diseases, and developed and disseminated two
antimalarial treatments, one new treatment against
sleeping sickness, one new treatment against
Visceral leishmaniasis, a set of treatments for Visceral leishmaniasis in Asia, and a pediatric dosage formulation for
Chagas Disease. These new drugs are now available to millions of people. DNDi also has a development portfolio of over 30 lead compounds targeting neglected diseases. == Academic career ==